Difference between revisions of "Sandbox:khurram"

Jump to: navigation, search
 
(111 intermediate revisions by 4 users not shown)
Line 1: Line 1:
__NOTOC__
+
{{CMG}}; {{AE}} {{MKA}}, {{S.G.}}
  
{{CMG}}; {{AE}}
+
===Differentiating [disease name] from other diseases on the basis of [symptom 1], [symptom 2], and [symptom 3]===
==Overview==
 
The pathogenesis of alcoholic liver disease is complex and still remains unclear, the metabolites of the oxidative metabolism in the liver; acetaldehyde and reactive oxygen species are thought to be involved in the toxic effects of ethanol on the liver.<ref name="pmid25548474">{{cite journal |vauthors=Ceni E, Mello T, Galli A |title=Pathogenesis of alcoholic liver disease: role of oxidative metabolism |journal=World J. Gastroenterol. |volume=20 |issue=47 |pages=17756–72 |year=2014 |pmid=25548474 |pmc=4273126 |doi=10.3748/wjg.v20.i47.17756 |url=}}</ref>
 
  
==Pathophysiology==
+
On the basis [symptom 1], [symptom 2], and [symptom 3], [disease name] must be differentiated from [disease 1], [disease 2], [disease 3], [disease 4], [disease 5], and [disease 6].
 +
{|
 +
|- style="background: #4479BA; color: #FFFFFF; text-align: center;"
 +
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diseases
 +
| colspan="6" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Clinical manifestations'''
 +
! colspan="4" rowspan="2" |Para-clinical findings
 +
| colspan="1" rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Gold standard'''
 +
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings
 +
|-
 +
| colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Symptoms'''
 +
| colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Physical examination'''
 +
|-
 +
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Lab Findings'''
 +
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Imaging'''
 +
|-
 +
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Symptoms of DVT
 +
! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Symptoms of Pulmonary Embolism
 +
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Symptoms of Myocardial Infarction
 +
! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Tenderness in extremities
 +
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Edema in extremities
 +
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Warmth in extremities
 +
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |PT
 +
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |aPTT
 +
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Doppler ultrasound
 +
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Chest CT scan
 +
|-
 +
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Antithrombin III deficiency]]<ref name="pmid19141163">{{cite journal |vauthors=Patnaik MM, Moll S |title=Inherited antithrombin deficiency: a review |journal=Haemophilia |volume=14 |issue=6 |pages=1229–39 |date=November 2008 |pmid=19141163 |doi=10.1111/j.1365-2516.2008.01830.x |url=}}</ref><ref name="Al HadidiWu2017">{{cite journal|last1=Al Hadidi|first1=Samer|last2=Wu|first2=Kristi|last3=Aburahma|first3=Ahmed|last4=Alamarat|first4=Zain|title=Family with clots: antithrombin deficiency|journal=BMJ Case Reports|year=2017|pages=bcr-2017-221556|issn=1757-790X|doi=10.1136/bcr-2017-221556}}</ref><ref name="pmid21772860">{{cite journal |vauthors=Konecny F |title=Inherited trombophilic states and pulmonary embolism |journal=J Res Med Sci |volume=14 |issue=1 |pages=43–56 |date=January 2009 |pmid=21772860 |pmc=3129068 |doi= |url=}}</ref>
  
===Pathogenesis===
+
| style="background: #F5F5F5; padding: 5px;" | +
*Ethanol metabolism in the liver is carried out mainly by two enzymes; alcohol dehydrogenase and aldehyde dehydrogenase. Both of these enzymes use NAD+ as a cofactor. Alcohol is converted to acetaldehyde and acetaldehyde is then further oxidized to acetate. Acetaldehyde is the toxic metabolite in this process.<ref name="pmid25548474">{{cite journal |vauthors=Ceni E, Mello T, Galli A |title=Pathogenesis of alcoholic liver disease: role of oxidative metabolism |journal=World J. Gastroenterol. |volume=20 |issue=47 |pages=17756–72 |year=2014 |pmid=25548474 |pmc=4273126 |doi=10.3748/wjg.v20.i47.17756 |url=}}</ref>
+
| style="background: #F5F5F5; padding: 5px;" | +
*The metabolism of alcohol in the liver ends up producing an excess of reduced nicotinamide adenine dinucleotide(NADH). This changes the reduction-oxidation potential in the liver and inhibits key metabolic processes in the liver such as, the tricarboxylic acid cycle and the oxidation of fatty acids and thereby ends up promoting lipogenesis.<ref name="pmid15194557">{{cite journal |vauthors=You M, Crabb DW |title=Recent advances in alcoholic liver disease II. Minireview: molecular mechanisms of alcoholic fatty liver |journal=Am. J. Physiol. Gastrointest. Liver Physiol. |volume=287 |issue=1 |pages=G1–6 |year=2004 |pmid=15194557 |doi=10.1152/ajpgi.00056.2004 |url=}}</ref>
+
| style="background: #F5F5F5; padding: 5px;" | -
*Since acetaldehyde has an electrophilic nature it can form covalent chemical bonds with proteins, lipids and DNA. These covalent bonds that are formed are extremely pathogenic, as they have the ability to alter cell environments, protein structures and they can enable DNA damage and mutation.<ref name="pmid16088993">{{cite journal |vauthors=Freeman TL, Tuma DJ, Thiele GM, Klassen LW, Worrall S, Niemelä O, Parkkila S, Emery PW, Preedy VR |title=Recent advances in alcohol-induced adduct formation |journal=Alcohol. Clin. Exp. Res. |volume=29 |issue=7 |pages=1310–6 |year=2005 |pmid=16088993 |doi= |url=}}</ref><ref name="pmid17590995">{{cite journal |vauthors=Niemelä O |title=Acetaldehyde adducts in circulation |journal=Novartis Found. Symp. |volume=285 |issue= |pages=183–92; discussion 193–7 |year=2007 |pmid=17590995 |doi= |url=}}</ref><ref name="pmid11841919">{{cite journal |vauthors=Tuma DJ |title=Role of malondialdehyde-acetaldehyde adducts in liver injury |journal=Free Radic. Biol. Med. |volume=32 |issue=4 |pages=303–8 |year=2002 |pmid=11841919 |doi= |url=}}</ref><ref name="pmid15540799">{{cite journal |vauthors=Tuma DJ, Casey CA |title=Dangerous byproducts of alcohol breakdown--focus on adducts |journal=Alcohol Res Health |volume=27 |issue=4 |pages=285–90 |year=2003 |pmid=15540799 |doi= |url=}}</ref><ref name="pmid16054980">{{cite journal |vauthors=Brooks PJ, Theruvathu JA |title=DNA adducts from acetaldehyde: implications for alcohol-related carcinogenesis |journal=Alcohol |volume=35 |issue=3 |pages=187–93 |year=2005 |pmid=16054980 |doi=10.1016/j.alcohol.2005.03.009 |url=}}</ref><ref name="pmid17718399">{{cite journal |vauthors=Seitz HK, Becker P |title=Alcohol metabolism and cancer risk |journal=Alcohol Res Health |volume=30 |issue=1 |pages=38–41, 44–7 |year=2007 |pmid=17718399 |pmc=3860434 |doi= |url=}}</ref><ref name="pmid9857222">{{cite journal |vauthors=Biewald J, Nilius R, Langner J |title=Occurrence of acetaldehyde protein adducts formed in various organs of chronically ethanol fed rats: an immunohistochemical study |journal=Int. J. Mol. Med. |volume=2 |issue=4 |pages=389–96 |year=1998 |pmid=9857222 |doi= |url=}}</ref><ref name="pmid17543846">{{cite journal |vauthors=Seitz HK, Meier P |title=The role of acetaldehyde in upper digestive tract cancer in alcoholics |journal=Transl Res |volume=149 |issue=6 |pages=293–7 |year=2007 |pmid=17543846 |doi=10.1016/j.trsl.2006.12.002 |url=}}</ref>
+
| style="background: #F5F5F5; padding: 5px;" | +
 +
| style="background: #F5F5F5; padding: 5px;" | +
 +
| style="background: #F5F5F5; padding: 5px;" | +
 +
| style="background: #F5F5F5; padding: 5px;" | Normal
 +
| style="background: #F5F5F5; padding: 5px;" |
 +
* Normal
  
*The cytochrome P450 enzymes (CYP) are a part of the microsomal ethanol oxidizing system. These are a large group of enzymes involved in numerous oxidizing reactions on different substrates. They catalyze many different reactions in order to make them in to more polar metabolites that are easier to excrete.<ref name="pmid3678578">{{cite journal |vauthors=Guengerich FP, Beaune PH, Umbenhauer DR, Churchill PF, Bork RW, Dannan GA, Knodell RG, Lloyd RS, Martin MV |title=Cytochrome P-450 enzymes involved in genetic polymorphism of drug oxidation in humans |journal=Biochem. Soc. Trans. |volume=15 |issue=4 |pages=576–8 |year=1987 |pmid=3678578 |doi= |url=}}</ref>
+
* Reduces the Increase in [[PTT]] after administration of [[heparin]]
 +
| style="background: #F5F5F5; padding: 5px;" |
 +
* Evidence of [[deep vein thrombosis]] ([[DVT]])
 +
* Should be used for diagnosis and follow up
 +
| style="background: #F5F5F5; padding: 5px;" |
 +
* [[Occlusion]] of  [[brachiocephalic]] [[vein]]
 +
* Large [[thrombus]] in [[superior vena cava]]
 +
| style="background: #F5F5F5; padding: 5px;" |
 +
* Decreased [[plasma]] [[Antithrombin III|antithrombin]] ([[AT III]]) activity
 +
| style="background: #F5F5F5; padding: 5px;" |
 +
* [[Nephrotic syndrome]]
 +
* Decreased inhibition of [[factor II]] and Xa
 +
* [[Antithrombin]] is a natural [[anticoagulant]] that is lost in the [[urine]]
 +
|-
 +
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Factor V Leiden mutation]]<ref name="pmid20626623">{{cite journal |vauthors=Mannucci PM, Asselta R, Duga S, Guella I, Spreafico M, Lotta L, Merlini PA, Peyvandi F, Kathiresan S, Ardissino D |title=The association of factor V Leiden with myocardial infarction is replicated in 1880 patients with premature disease |journal=J. Thromb. Haemost. |volume=8 |issue=10 |pages=2116–21 |date=October 2010 |pmid=20626623 |doi=10.1111/j.1538-7836.2010.03982.x |url=}}</ref><ref name="pmid27797270">{{cite journal |vauthors=Campello E, Spiezia L, Simioni P |title=Diagnosis and management of factor V Leiden |journal=Expert Rev Hematol |volume=9 |issue=12 |pages=1139–1149 |date=December 2016 |pmid=27797270 |doi=10.1080/17474086.2016.1249364 |url=}}</ref><ref name="pmid15003896">{{cite journal |vauthors=Van Rooden CJ, Rosendaal FR, Meinders AE, Van Oostayen JA, Van Der Meer FJ, Huisman MV |title=The contribution of factor V Leiden and prothrombin G20210A mutation to the risk of central venous catheter-related thrombosis |journal=Haematologica |volume=89 |issue=2 |pages=201–6 |date=February 2004 |pmid=15003896 |doi= |url=}}</ref><ref name="pmid23615845">{{cite journal| author=Dentali F, Pomero F, Borretta V, Gianni M, Squizzato A, Fenoglio L et al.| title=Location of venous thrombosis in patients with FVL or prothrombin G20210A mutations: systematic review and meta-analysis. | journal=Thromb Haemost | year= 2013 | volume= 110 | issue= 1 | pages= 191-4 | pmid=23615845 | doi=10.1160/TH13-02-0163 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23615845  }}</ref><ref name="pmid12421138">{{cite journal |vauthors=Press RD, Bauer KA, Kujovich JL, Heit JA |title=Clinical utility of factor V leiden (R506Q) testing for the diagnosis and management of thromboembolic disorders |journal=Arch. Pathol. Lab. Med. |volume=126 |issue=11 |pages=1304–18 |date=November 2002 |pmid=12421138 |doi=10.1043/0003-9985(2002)126<1304:CUOFVL>2.0.CO;2 |url=}}</ref>
 +
| style="background: #F5F5F5; padding: 5px;" | +
 +
| style="background: #F5F5F5; padding: 5px;" | +
 +
| style="background: #F5F5F5; padding: 5px;" | +
 +
| style="background: #F5F5F5; padding: 5px;" | +
 +
| style="background: #F5F5F5; padding: 5px;" | +
 +
| style="background: #F5F5F5; padding: 5px;" | +
 +
| style="background: #F5F5F5; padding: 5px;" |N/A
 +
| style="background: #F5F5F5; padding: 5px;" |↑
 +
| style="background: #F5F5F5; padding: 5px;" |
 +
* Recommended to do weekly
 +
* [[Proximal]] [[DVT]] is more commonly observed as compared to [[distal]] [[DVT]]
 +
| style="background: #F5F5F5; padding: 5px;" |
 +
* [[Pulmonary embolism]]
 +
| style="background: #F5F5F5; padding: 5px;" |
 +
* N/A
 +
| style="background: #F5F5F5; padding: 5px;" |
 +
* Inactivates factor Va and factor VIIIa
 +
|-
 +
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Protein C deficiency]]<ref>{{Cite journal
 +
| author = [[Bernard Khor]] & [[Elizabeth M. Van Cott]]
 +
| title = Laboratory tests for protein C deficiency
 +
| journal = [[American journal of hematology]]
 +
| volume = 85
 +
| issue = 6
 +
| pages = 440–442
 +
| year = 2010
 +
| month = June
 +
| doi = 10.1002/ajh.21679
 +
| pmid = 20309856
 +
}}</ref><ref name="pmid11336597">{{cite journal |vauthors=Pescatore SL |title=Clinical management of protein C deficiency |journal=Expert Opin Pharmacother |volume=2 |issue=3 |pages=431–9 |date=March 2001 |pmid=11336597 |doi=10.1517/14656566.2.3.431 |url=}}</ref><ref name=":0">{{Cite journal
 +
| author = [[Gustavo A. Rodriguez-Leal]], [[Segundo Moran]], [[Roberto Corona-Cedillo]] & [[Rocio Brom-Valladares]]
 +
| title = Portal vein thrombosis with protein C-S deficiency in a non-cirrhotic patient
 +
| journal = [[World journal of hepatology]]
 +
| volume = 6
 +
| issue = 7
 +
| pages = 532–537
 +
| year = 2014
 +
| month = July
 +
| doi = 10.4254/wjh.v6.i7.532
 +
| pmid = 25068006
 +
}}</ref>
 +
| style="background: #F5F5F5; padding: 5px;" | +
 +
| style="background: #F5F5F5; padding: 5px;" | +
 +
| style="background: #F5F5F5; padding: 5px;" | -
 +
| style="background: #F5F5F5; padding: 5px;" | +
 +
| style="background: #F5F5F5; padding: 5px;" | +
 +
| style="background: #F5F5F5; padding: 5px;" | +
 +
| style="background: #F5F5F5; padding: 5px;" | Normal
 +
| style="background: #F5F5F5; padding: 5px;" |Normal / ↑
 +
| style="background: #F5F5F5; padding: 5px;" |
 +
* [[Hypercoagulation]]
 +
* Recurrent [[venous thromboembolism]]
 +
| style="background: #F5F5F5; padding: 5px;" |
 +
* [[Venous thromboembolism]]
 +
* [[Pulmonary embolism]]
 +
| style="background: #F5F5F5; padding: 5px;" |
 +
* [[Protein C]] functional [[assay]]
 +
* [[ELISA]] [[assay]]: may produce [[false positive]] result in cross reaction with [[rheumatoid factor]]
 +
| style="background: #F5F5F5; padding: 5px;" |
 +
* [[Factor VIII]] elevation in acute phase
 +
* Functional [[assay]] should not be performed if patient is on [[warfarin]]
 +
* [[Purpura fulminans]] ([[skin]] [[necrosis]]) could be a form of presentation
 +
* Risk of [[thrombotic]] [[skin]] [[necrosis]] following [[warfarin]] administration
 +
|-
 +
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Protein S deficiency]]<ref name=":0" /><ref>{{Cite journal
 +
| author = [[Kristi J. Smock]], [[Elizabeth A. Plumhoff]], [[Piet Meijer]], [[Peihong Hsu]], [[Nicole D. Zantek]], [[Nahla M. Heikal]] & [[Elizabeth M. Van Cott]]
 +
| title = Protein S testing in patients with protein S deficiency, factor V Leiden, and rivaroxaban by North American Specialized Coagulation Laboratories
 +
| journal = [[Thrombosis and haemostasis]]
 +
| volume = 116
 +
| issue = 1
 +
| pages = 50–57
 +
| year = 2016
 +
| month = July
 +
| doi = 10.1160/TH15-12-0918
 +
| pmid = 27075008
 +
}}</ref><ref name="pmid21799399">{{cite journal |vauthors=Ji M, Yoon SN, Lee W, Jang S, Park SH, Kim DY, Chun S, Min WK |title=Protein S deficiency with a PROS1 gene mutation in a patient presenting with mesenteric venous thrombosis following total colectomy |journal=Blood Coagul. Fibrinolysis |volume=22 |issue=7 |pages=619–21 |date=October 2011 |pmid=21799399 |doi=10.1097/MBC.0b013e32834a0421 |url=}}</ref>
 +
| style="background: #F5F5F5; padding: 5px;" | +
 +
| style="background: #F5F5F5; padding: 5px;" | +
 +
| style="background: #F5F5F5; padding: 5px;" | -
 +
| style="background: #F5F5F5; padding: 5px;" | +
 +
| style="background: #F5F5F5; padding: 5px;" | +
 +
| style="background: #F5F5F5; padding: 5px;" | +
 +
| style="background: #F5F5F5; padding: 5px;" |Normal
 +
| style="background: #F5F5F5; padding: 5px;" |Normal / ↑
 +
| style="background: #F5F5F5; padding: 5px;" |
 +
* [[Hypercoagulation]]
 +
* Recurrent [[venous thromboembolism]]
 +
| style="background: #F5F5F5; padding: 5px;" |
 +
* [[Pulmonary embolism]]
 +
* [[Thrombosis]] of [[superior mesenteric vein]]
 +
| style="background: #F5F5F5; padding: 5px;" |
 +
* [[Protein S]] free [[antigen]] [[assay]]
 +
| style="background: #F5F5F5; padding: 5px;" |
 +
* When performing the gold standard test, beware of interference from samples positive for [[Factor V]] [[mutation]], [[protein C deficiency]] and oral [[anticoagulants]] ([[rivaroxaban]])
 +
* Risk of [[thrombotic]] [[skin]] [[necrosis]] following [[warfarin]] administration
 +
* Suspected in patients with a strong family history of [[VTE]]
 +
* [[Post phlebitic syndrome]] 
  
*There is an ethanol inducible form of CYP enzymes that is working in a small amount under normal physiological conditions. This enzyme CYP2E1 is converting ethanol to acetaldehyde and then to acetate. When there is chronic alcohol abuse, there is induction of the microsomal system and there is an increase in the expression of CYP2E1. This increase in CYP2E1 expression under chronic ethanol consumption can be hazardous, as this oxidation reaction can produces many different ROS; O<sub>2</sub><sup>-</sup>, H<sub>2</sub>O<sub>2</sub>, OH<sup>-</sup> and hydroxyethyl radical (HER).<ref name="pmid36785782">{{cite journal |vauthors=Guengerich FP, Beaune PH, Umbenhauer DR, Churchill PF, Bork RW, Dannan GA, Knodell RG, Lloyd RS, Martin MV |title=Cytochrome P-450 enzymes involved in genetic polymorphism of drug oxidation in humans |journal=Biochem. Soc. Trans. |volume=15 |issue=4 |pages=576–8 |year=1987 |pmid=3678578 |doi= |url=}}</ref><ref name="pmid5009602">{{cite journal |vauthors=Lieber CS |title=Metabolism of ethanol and alcoholism: racial and acquired factors |journal=Ann. Intern. Med. |volume=76 |issue=2 |pages=326–7 |year=1972 |pmid=5009602 |doi= |url=}}</ref><ref name="pmid4402282">{{cite journal |vauthors=Lieber CS, DeCarli LM |title=The role of the hepatic microsomal ethanol oxidizing system (MEOS) for ethanol metabolism in vivo |journal=J. Pharmacol. Exp. Ther. |volume=181 |issue=2 |pages=279–87 |year=1972 |pmid=4402282 |doi= |url=}}</ref><ref name="pmid9114822">{{cite journal |vauthors=Lieber CS |title=Cytochrome P-4502E1: its physiological and pathological role |journal=Physiol. Rev. |volume=77 |issue=2 |pages=517–44 |year=1997 |pmid=9114822 |doi= |url=}}</ref><ref name="pmid2333153">{{cite journal |vauthors=Hansson T, Tindberg N, Ingelman-Sundberg M, Köhler C |title=Regional distribution of ethanol-inducible cytochrome P450 IIE1 in the rat central nervous system |journal=Neuroscience |volume=34 |issue=2 |pages=451–63 |year=1990 |pmid=2333153 |doi= |url=}}</ref><ref name="pmid17760783">{{cite journal |vauthors=Donohue TM, Cederbaum AI, French SW, Barve S, Gao B, Osna NA |title=Role of the proteasome in ethanol-induced liver pathology |journal=Alcohol. Clin. Exp. Res. |volume=31 |issue=9 |pages=1446–59 |year=2007 |pmid=17760783 |doi=10.1111/j.1530-0277.2007.00454.x |url=}}</ref><ref name="pmid17854134">{{cite journal |vauthors=Osna NA, Donohue TM |title=Implication of altered proteasome function in alcoholic liver injury |journal=World J. Gastroenterol. |volume=13 |issue=37 |pages=4931–7 |year=2007 |pmid=17854134 |pmc=4434615 |doi= |url=}}</ref><ref name="pmid18078827">{{cite journal |vauthors=Lu Y, Cederbaum AI |title=CYP2E1 and oxidative liver injury by alcohol |journal=Free Radic. Biol. Med. |volume=44 |issue=5 |pages=723–38 |year=2008 |pmid=18078827 |pmc=2268632 |doi=10.1016/j.freeradbiomed.2007.11.004 |url=}}</ref><ref name="pmid1545775">{{cite journal |vauthors=Yun YP, Casazza JP, Sohn DH, Veech RL, Song BJ |title=Pretranslational activation of cytochrome P450IIE during ketosis induced by a high fat diet |journal=Mol. Pharmacol. |volume=41 |issue=3 |pages=474–9 |year=1992 |pmid=1545775 |doi= |url=}}</ref><ref name="pmid2005876">{{cite journal |vauthors=Raucy JL, Lasker JM, Kraner JC, Salazar DE, Lieber CS, Corcoran GB |title=Induction of cytochrome P450IIE1 in the obese overfed rat |journal=Mol. Pharmacol. |volume=39 |issue=3 |pages=275–80 |year=1991 |pmid=2005876 |doi= |url=}}</ref><ref name="pmid11826398">{{cite journal |vauthors=Woodcroft KJ, Hafner MS, Novak RF |title=Insulin signaling in the transcriptional and posttranscriptional regulation of CYP2E1 expression |journal=Hepatology |volume=35 |issue=2 |pages=263–73 |year=2002 |pmid=11826398 |doi=10.1053/jhep.2002.30691 |url=}}</ref><ref name="pmid7700245">{{cite journal |vauthors=De Waziers I, Garlatti M, Bouguet J, Beaune PH, Barouki R |title=Insulin down-regulates cytochrome P450 2B and 2E expression at the post-transcriptional level in the rat hepatoma cell line |journal=Mol. Pharmacol. |volume=47 |issue=3 |pages=474–9 |year=1995 |pmid=7700245 |doi= |url=}}</ref><ref name="pmid9765518">{{cite journal |vauthors=Peng HM, Coon MJ |title=Regulation of rabbit cytochrome P450 2E1 expression in HepG2 cells by insulin and thyroid hormone |journal=Mol. Pharmacol. |volume=54 |issue=4 |pages=740–7 |year=1998 |pmid=9765518 |doi= |url=}}</ref><ref name="pmid1822117">{{cite journal |vauthors=Terelius Y, Norsten-Höög C, Cronholm T, Ingelman-Sundberg M |title=Acetaldehyde as a substrate for ethanol-inducible cytochrome P450 (CYP2E1) |journal=Biochem. Biophys. Res. Commun. |volume=179 |issue=1 |pages=689–94 |year=1991 |pmid=1822117 |doi= |url=}}</ref><ref name="pmid9726291">{{cite journal |vauthors=Wu YS, Salmela KS, Lieber CS |title=Microsomal acetaldehyde oxidation is negligible in the presence of ethanol |journal=Alcohol. Clin. Exp. Res. |volume=22 |issue=5 |pages=1165–9 |year=1998 |pmid=9726291 |doi= |url=}}</ref><ref name="pmid9309320">{{cite journal |vauthors=Brooks PJ |title=DNA damage, DNA repair, and alcohol toxicity--a review |journal=Alcohol. Clin. Exp. Res. |volume=21 |issue=6 |pages=1073–82 |year=1997 |pmid=9309320 |doi= |url=}}</ref>
+
* [[Fetal]] loss
 
+
|-
*Ethanol metabolism additionally promotes lipogenesis through the inhibition of peroxisome proliferator activated receptor α (PPAR-α) and AMP kinase, as well as the stimulation of sterol regulatory element binding protein 1, which is a membrane bound transcription factor. The sequence of all these events results in a fat storing metabolic remodeling of the liver.<ref name="pmid12791698">{{cite journal |vauthors=Fischer M, You M, Matsumoto M, Crabb DW |title=Peroxisome proliferator-activated receptor alpha (PPARalpha) agonist treatment reverses PPARalpha dysfunction and abnormalities in hepatic lipid metabolism in ethanol-fed mice |journal=J. Biol. Chem. |volume=278 |issue=30 |pages=27997–8004 |year=2003 |pmid=12791698 |doi=10.1074/jbc.M302140200 |url=}}</ref><ref name="pmid15578517">{{cite journal |vauthors=You M, Matsumoto M, Pacold CM, Cho WK, Crabb DW |title=The role of AMP-activated protein kinase in the action of ethanol in the liver |journal=Gastroenterology |volume=127 |issue=6 |pages=1798–808 |year=2004 |pmid=15578517 |doi= |url=}}</ref><ref name="pmid16879892">{{cite journal |vauthors=Ji C, Chan C, Kaplowitz N |title=Predominant role of sterol response element binding proteins (SREBP) lipogenic pathways in hepatic steatosis in the murine intragastric ethanol feeding model |journal=J. Hepatol. |volume=45 |issue=5 |pages=717–24 |year=2006 |pmid=16879892 |doi=10.1016/j.jhep.2006.05.009 |url=}}</ref>
+
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Prothrombin gene mutation G20210A|Prothrombin gene mutation]]<ref name="pmid17474891">{{cite journal| author=Cooper PC, Rezende SM| title=An overview of methods for detection of factor V Leiden and the prothrombin G20210A mutations. | journal=Int J Lab Hematol | year= 2007 | volume= 29 | issue= 3 | pages= 153-62 | pmid=17474891 | doi=10.1111/j.1751-553X.2007.00892.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17474891  }}</ref><ref name="pmid12421139">{{cite journal| author=McGlennen RC, Key NS| title=Clinical and laboratory management of the prothrombin G20210A mutation. | journal=Arch Pathol Lab Med | year= 2002 | volume= 126 | issue= 11 | pages= 1319-25 | pmid=12421139 | doi=10.1043/0003-9985(2002)126<1319:CALMOT>2.0.CO;2 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12421139  }}</ref><ref name="pmid236158452">{{cite journal| author=Dentali F, Pomero F, Borretta V, Gianni M, Squizzato A, Fenoglio L et al.| title=Location of venous thrombosis in patients with FVL or prothrombin G20210A mutations: systematic review and meta-analysis. | journal=Thromb Haemost | year= 2013 | volume= 110 | issue= 1 | pages= 191-4 | pmid=23615845 | doi=10.1160/TH13-02-0163 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23615845  }}</ref>
 
+
| style="background: #F5F5F5; padding: 5px;" | +
*Based on animal studies, 2 key factors that play an important role in the inflammatory process that leads to the alcohol mediated liver injury are endotoxin and gut permeability. Endotoxin is associated to the lipopolysaccharide (LPS) component of the outer wall of gram-negative bacteria and is thought to be the key trigger in this inflammatory process. Gut permeability is the factor that is either enabling or preventing the transfer of the LPS-endotoxin from the intestinal lumen into the portal circulation, it is seen to be altered in response to long term exposure to alcohol. This fact has been observed in humans as gut permeability and LPS-endotoxin levels have been found to be elevated in patients with alcoholic liver injury.<ref name="pmid6433728">{{cite journal |vauthors=Tsukamoto H, Reidelberger RD, French SW, Largman C |title=Long-term cannulation model for blood sampling and intragastric infusion in the rat |journal=Am. J. Physiol. |volume=247 |issue=3 Pt 2 |pages=R595–9 |year=1984 |pmid=6433728 |doi= |url=}}</ref><ref name="pmid11431739">{{cite journal |vauthors=Uesugi T, Froh M, Arteel GE, Bradford BU, Thurman RG |title=Toll-like receptor 4 is involved in the mechanism of early alcohol-induced liver injury in mice |journal=Hepatology |volume=34 |issue=1 |pages=101–8 |year=2001 |pmid=11431739 |doi=10.1053/jhep.2001.25350 |url=}}</ref><ref name="pmid15723320">{{cite journal |vauthors=Wiest R, Garcia-Tsao G |title=Bacterial translocation (BT) in cirrhosis |journal=Hepatology |volume=41 |issue=3 |pages=422–33 |year=2005 |pmid=15723320 |doi=10.1002/hep.20632 |url=}}</ref><ref name="pmid8171045">{{cite journal |vauthors=Nanji AA, Khettry U, Sadrzadeh SM |title=Lactobacillus feeding reduces endotoxemia and severity of experimental alcoholic liver (disease) |journal=Proc. Soc. Exp. Biol. Med. |volume=205 |issue=3 |pages=243–7 |year=1994 |pmid=8171045 |doi= |url=}}</ref><ref name="pmid7806045">{{cite journal |vauthors=Adachi Y, Moore LE, Bradford BU, Gao W, Thurman RG |title=Antibiotics prevent liver injury in rats following long-term exposure to ethanol |journal=Gastroenterology |volume=108 |issue=1 |pages=218–24 |year=1995 |pmid=7806045 |doi= |url=}}</ref><ref name="pmid6141332">{{cite journal |vauthors=Bjarnason I, Peters TJ, Wise RJ |title=The leaky gut of alcoholism: possible route of entry for toxic compounds |journal=Lancet |volume=1 |issue=8370 |pages=179–82 |year=1984 |pmid=6141332 |doi= |url=}}</ref><ref name="pmid11236841">{{cite journal |vauthors=Urbaschek R, McCuskey RS, Rudi V, Becker KP, Stickel F, Urbaschek B, Seitz HK |title=Endotoxin, endotoxin-neutralizing-capacity, sCD14, sICAM-1, and cytokines in patients with various degrees of alcoholic liver disease |journal=Alcohol. Clin. Exp. Res. |volume=25 |issue=2 |pages=261–8 |year=2001 |pmid=11236841 |doi= |url=}}</ref>
+
| style="background: #F5F5F5; padding: 5px;" | +
 
+
| style="background: #F5F5F5; padding: 5px;" | -
*Experimental studies in animals have led to a better understanding of the disease process and how the factors mentioned above contribute to these processes. After the entry of LPS-endotoxin in to the portal circulation it binds to the LPS-binding protein, this is a key step in the inflammatory and histopathological response to alcohol ingestion.The LPS-Lps binding protein complex binds to the CD14 receptor on the cell surface membrane of the Kupffer cells in the liver. Activation of these Kupffer cells requires 3 main cellular proteins: CD 14 (monocyte differentiation antigen), toll-like receptor 4 (TLR4) and a protein known as MD2, this protein binds TLR4 with LPS-LPS binding protein. The TLR4 then signals activation of early growth response 1 (EGR1), which is an early gene-zinc-finger transcription factor. The nuclear factor-kB (NF-kB) and the TLR4 adapter also play an important role in the activation of the kupffer cells. EGR1 plays the pivotal role in lipopolysaccharide-stimulated TNF-α production; in mice the absence of EGR1 prevents alcohol induced liver injury.<ref name="pmid11884468">{{cite journal |vauthors=Uesugi T, Froh M, Arteel GE, Bradford BU, Wheeler MD, Gäbele E, Isayama F, Thurman RG |title=Role of lipopolysaccharide-binding protein in early alcohol-induced liver injury in mice |journal=J. Immunol. |volume=168 |issue=6 |pages=2963–9 |year=2002 |pmid=11884468 |doi= |url=}}</ref><ref name="pmid8045507">{{cite journal |vauthors=Adachi Y, Bradford BU, Gao W, Bojes HK, Thurman RG |title=Inactivation of Kupffer cells prevents early alcohol-induced liver injury |journal=Hepatology |volume=20 |issue=2 |pages=453–60 |year=1994 |pmid=8045507 |doi= |url=}}</ref><ref name="pmid11477402">{{cite journal |vauthors=Akira S, Takeda K, Kaisho T |title=Toll-like receptors: critical proteins linking innate and acquired immunity |journal=Nat. Immunol. |volume=2 |issue=8 |pages=675–80 |year=2001 |pmid=11477402 |doi=10.1038/90609 |url=}}</ref><ref name="pmid11254735">{{cite journal |vauthors=Yin M, Bradford BU, Wheeler MD, Uesugi T, Froh M, Goyert SM, Thurman RG |title=Reduced early alcohol-induced liver injury in CD14-deficient mice |journal=J. Immunol. |volume=166 |issue=7 |pages=4737–42 |year=2001 |pmid=11254735 |doi= |url=}}</ref><ref name="pmid15940638">{{cite journal |vauthors=McMullen MR, Pritchard MT, Wang Q, Millward CA, Croniger CM, Nagy LE |title=Early growth response-1 transcription factor is essential for ethanol-induced fatty liver injury in mice |journal=Gastroenterology |volume=128 |issue=7 |pages=2066–76 |year=2005 |pmid=15940638 |pmc=1959407 |doi= |url=}}</ref><ref name="pmid18713975">{{cite journal |vauthors=Zhao XJ, Dong Q, Bindas J, Piganelli JD, Magill A, Reiser J, Kolls JK |title=TRIF and IRF-3 binding to the TNF promoter results in macrophage TNF dysregulation and steatosis induced by chronic ethanol |journal=J. Immunol. |volume=181 |issue=5 |pages=3049–56 |year=2008 |pmid=18713975 |pmc=3690475 |doi= |url=}}</ref><ref name="pmid18792393">{{cite journal |vauthors=Hritz I, Mandrekar P, Velayudham A, Catalano D, Dolganiuc A, Kodys K, Kurt-Jones E, Szabo G |title=The critical role of toll-like receptor (TLR) 4 in alcoholic liver disease is independent of the common TLR adapter MyD88 |journal=Hepatology |volume=48 |issue=4 |pages=1224–31 |year=2008 |pmid=18792393 |doi=10.1002/hep.22470 |url=}}</ref>
+
| style="background: #F5F5F5; padding: 5px;" | +
 
+
| style="background: #F5F5F5; padding: 5px;" | +
*Ethanol administration stimulates the release of mitochondrial cytochrome c and the expression of the Fas ligand, this leads to hepatic cell apoptosis mediated by the cascade-3 activation pathway. The cumulative effect of TNF-α and Fas-mediated apoptotic signals make the hepatocytes more susceptible to injury by stimulating an increase in natural killer T cells in the liver.<ref name="pmid11438480">{{cite journal |vauthors=Zhou Z, Sun X, Kang YJ |title=Ethanol-induced apoptosis in mouse liver: Fas- and cytochrome c-mediated caspase-3 activation pathway |journal=Am. J. Pathol. |volume=159 |issue=1 |pages=329–38 |year=2001 |pmid=11438480 |pmc=1850406 |doi=10.1016/S0002-9440(10)61699-9 |url=}}</ref><ref name="pmid15131799">{{cite journal |vauthors=Minagawa M, Deng Q, Liu ZX, Tsukamoto H, Dennert G |title=Activated natural killer T cells induce liver injury by Fas and tumor necrosis factor-alpha during alcohol consumption |journal=Gastroenterology |volume=126 |issue=5 |pages=1387–99 |year=2004 |pmid=15131799 |doi= |url=}}</ref>
+
| style="background: #F5F5F5; padding: 5px;" | +
 
+
| style="background: #F5F5F5; padding: 5px;" |
 
+
| style="background: #F5F5F5; padding: 5px;" |N/A
 
+
| style="background: #F5F5F5; padding: 5px;" |
 
+
* [[Proximal]] [[DVT]] is more commonly observed as compared to [[distal]] [[DVT]]
 
+
| style="background: #F5F5F5; padding: 5px;" |
 
+
* [[Pulmonary embolism]]
 
+
| style="background: #F5F5F5; padding: 5px;" |
==Genetics==
+
* Detection of [[mutation]] using [[restriction enzyme]] and [[PCR]]
*[Disease name] is transmitted in [mode of genetic transmission] pattern.
+
* [[DNA testing]] for [[prothrombin G20210A mutation]]
*Genes involved in the pathogenesis of [disease name] include [gene1], [gene2], and [gene3].
+
| style="background: #F5F5F5; padding: 5px;" |
*The development of [disease name] is the result of multiple genetic mutations.
+
* [[Mutation]] causes increased production of [[prothrombin]]
 
+
* Increased [[blood]] levels of [[prothrombin]] lead to [[venous]] clots in the [[circulatory system]]
==Associated Conditions==
+
* [[Hormonal]] [[oral contraceptive pills]] can increase the risk of [[VTE]]
 
+
|-
==Gross Pathology==
+
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Disseminated intravascular coagulation|Disseminated intravascular coagulation (DIC)]]<ref name="pmid25535423">{{cite journal |vauthors=Venugopal A |title=Disseminated intravascular coagulation |journal=Indian J Anaesth |volume=58 |issue=5 |pages=603–8 |date=September 2014 |pmid=25535423 |pmc=4260307 |doi=10.4103/0019-5049.144666 |url=}}</ref><ref name="pmid27276832">{{cite journal |vauthors=Makruasi N |title=Treatment of Disseminated Intravascular Coagulation |journal=J Med Assoc Thai |volume=98 Suppl 10 |issue= |pages=S45–51 |date=November 2015 |pmid=27276832 |doi= |url=}}</ref><ref name="pmid29178991">{{cite journal| author=Cui S, Fu Z, Feng Y, Xie X, Ma X, Liu T et al.| title=The disseminated intravascular coagulation score is a novel predictor for portal vein thrombosis in cirrhotic patients with hepatitis B. | journal=Thromb Res | year= 2018 | volume= 161 | issue= | pages= 7-11 | pmid=29178991 | doi=10.1016/j.thromres.2017.11.010 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29178991  }}</ref>
*On gross pathology, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
+
| style="background: #F5F5F5; padding: 5px;" | +
 
+
| style="background: #F5F5F5; padding: 5px;" | +
==Microscopic Pathology==
+
| style="background: #F5F5F5; padding: 5px;" | +/-
*On microscopic histopathological analysis, steatosis (macrovesicular steatosis-the cytoplasm of hepatocytes is occupied by large lipid droplets that end up displacing the nucleus and other organelles peripherally), proliferation of the smooth endoplasmic reticulum, distortion of the mitochondria (giant mitochondria) and hepatocyte balooning (Mallory-Denk bodies) are characteristic findings of alcoholic liver disease.<ref name="pmid15763228">{{cite journal |vauthors=Lefkowitch JH |title=Morphology of alcoholic liver disease |journal=Clin Liver Dis |volume=9 |issue=1 |pages=37–53 |year=2005 |pmid=15763228 |doi=10.1016/j.cld.2004.11.001 |url=}}</ref><ref name="pmid5641156">{{cite journal |vauthors=Rubin E, Lieber CS |title=Alcohol-induced hepatic injury in nonalcoholic volunteers |journal=N. Engl. J. Med. |volume=278 |issue=16 |pages=869–76 |year=1968 |pmid=5641156 |doi=10.1056/NEJM196804182781602 |url=}}</ref><ref name="pmid7806041">{{cite journal |vauthors=Fromenty B, Grimbert S, Mansouri A, Beaugrand M, Erlinger S, Rötig A, Pessayre D |title=Hepatic mitochondrial DNA deletion in alcoholics: association with microvesicular steatosis |journal=Gastroenterology |volume=108 |issue=1 |pages=193–200 |year=1995 |pmid=7806041 |doi= |url=}}</ref><ref name="pmid3699404">{{cite journal |vauthors=Chedid A, Mendenhall CL, Tosch T, Chen T, Rabin L, Garcia-Pont P, Goldberg SJ, Kiernan T, Seeff LB, Sorrell M |title=Significance of megamitochondria in alcoholic liver disease |journal=Gastroenterology |volume=90 |issue=6 |pages=1858–64 |year=1986 |pmid=3699404 |doi= |url=}}</ref><ref name="pmid6700382">{{cite journal |vauthors=Uchida T, Kronborg I, Peters RL |title=Giant mitochondria in the alcoholic liver diseases--their identification, frequency and pathologic significance |journal=Liver |volume=4 |issue=1 |pages=29–38 |year=1984 |pmid=6700382 |doi= |url=}}</ref>
+
| style="background: #F5F5F5; padding: 5px;" | +
 
+
| style="background: #F5F5F5; padding: 5px;" | +
*A cirrhotic liver will show fibrous septae that are made up of collagen surrounding the hepatocytes which results in pseudo lobule formation. This produces a nodular appearance of the liver and then progresses from micro nodular to macro nodular cirrhosis with time. Proliferation of the bile ducts may also be seen.<ref name="pmid6629323">{{cite journal |vauthors=Fauerholdt L, Schlichting P, Christensen E, Poulsen H, Tygstrup N, Juhl E |title=Conversion of micronodular cirrhosis into macronodular cirrhosis |journal=Hepatology |volume=3 |issue=6 |pages=928–31 |year=1983 |pmid=6629323 |doi= |url=}}</ref><ref name="pmid649765">{{cite journal |vauthors=Anthony PP, Ishak KG, Nayak NC, Poulsen HE, Scheuer PJ, Sobin LH |title=The morphology of cirrhosis. Recommendations on definition, nomenclature, and classification by a working group sponsored by the World Health Organization |journal=J. Clin. Pathol. |volume=31 |issue=5 |pages=395–414 |year=1978 |pmid=649765 |pmc=1145292 |doi= |url=}}</ref><ref name="pmid2466751">{{cite journal |vauthors=Van Eyken P, Sciot R, Desmet VJ |title=A cytokeratin immunohistochemical study of alcoholic liver disease: evidence that hepatocytes can express 'bile duct-type' cytokeratins |journal=Histopathology |volume=13 |issue=6 |pages=605–17 |year=1988 |pmid=2466751 |doi= |url=}}</ref>
+
| style="background: #F5F5F5; padding: 5px;" | +
 +
| style="background: #F5F5F5; padding: 5px;" |↑
 +
| style="background: #F5F5F5; padding: 5px;" |
 +
| style="background: #F5F5F5; padding: 5px;" |
 +
* [[Portal vein thrombosis]] is observed in patients with coexistent [[hepatitis B]]
 +
| style="background: #F5F5F5; padding: 5px;" |
 +
* [[Pulmonary embolism]]
 +
| style="background: #F5F5F5; padding: 5px;" |
 +
* N/A
 +
| style="background: #F5F5F5; padding: 5px;" |
 +
* Elevated [[fibrin degradation products]] ([[D-dimers]])
 +
* Decreased [[fibrinogen]]
 +
* Decreased [[factor V]] and VIII
 +
* Shistocytes (helmet [[cells]]) on [[peripheral blood smear]]
 +
* [[Portal vein thrombosis]]
 +
|-
 +
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Antiphospholipid  antibody syndrome]]<ref name="pmid24319251">{{cite journal |vauthors=Lim W |title=Antiphospholipid syndrome |journal=Hematology Am Soc Hematol Educ Program |volume=2013 |issue= |pages=675–80 |date=2013 |pmid=24319251 |doi=10.1182/asheducation-2013.1.675 |url=}}</ref><ref name="pmid19624461">{{cite journal |vauthors=Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M, De Groot PG |title=Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis |journal=J. Thromb. Haemost. |volume=7 |issue=10 |pages=1737–40 |date=October 2009 |pmid=19624461 |doi=10.1111/j.1538-7836.2009.03555.x |url=}}</ref><ref name="pmid243192512">{{cite journal| author=Lim W| title=Antiphospholipid syndrome. | journal=Hematology Am Soc Hematol Educ Program | year= 2013 | volume= 2013 | issue= | pages= 675-80 | pmid=24319251 | doi=10.1182/asheducation-2013.1.675 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24319251  }}</ref><ref name="pmid29791828">{{cite journal| author=Garcia D, Erkan D| title=Diagnosis and Management of the Antiphospholipid Syndrome. | journal=N Engl J Med | year= 2018 | volume= 378 | issue= 21 | pages= 2010-2021 | pmid=29791828 | doi=10.1056/NEJMra1705454 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29791828  }}</ref><ref name="pmid23488294">{{cite journal| author=Kornacki J, Wirstlein P, Skrzypczak J| title=[Assessment of uterine arteries Doppler in the first half of pregnancy in women with thrombophilia]. | journal=Ginekol Pol | year= 2012 | volume= 83 | issue= 12 | pages= 916-21 | pmid=23488294 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23488294  }}</ref>
 +
| style="background: #F5F5F5; padding: 5px;" | +
 +
| style="background: #F5F5F5; padding: 5px;" | +
 +
| style="background: #F5F5F5; padding: 5px;" | +/-
 +
| style="background: #F5F5F5; padding: 5px;" | +
 +
| style="background: #F5F5F5; padding: 5px;" | +
 +
| style="background: #F5F5F5; padding: 5px;" | +
 +
| style="background: #F5F5F5; padding: 5px;" |N/A
 +
| style="background: #F5F5F5; padding: 5px;" |↑
 +
| style="background: #F5F5F5; padding: 5px;" |
 +
* Increased impedance of [[flow]] in [[uterine]] [[arteries]] at 12-20 weeks of [[gestation]]
 +
| style="background: #F5F5F5; padding: 5px;" |
 +
* [[Pulmonary embolism]]
 +
| style="background: #F5F5F5; padding: 5px;" |
 +
* [[Antiphospholipid antibody]]
 +
* [[Anticardiolipin antibody]]
 +
* [[Lupus anticoagulant]]
 +
* Anti-β2GPI [[antibody]]
 +
| style="background: #F5F5F5; padding: 5px;" |
 +
* Both, [[arterial]] and [[venous]] [[thrombosis]] can occur
 +
* History of [[spontaneous abortions]]
 +
* [[False positive]] [[VDRL]]
 +
* [[Stroke]] and [[transient ischemic attack]] ([[TIA]]) are most common forms of presentation of [[arterial thrombosis]]
 +
|}
  
 
==References==
 
==References==
Line 50: Line 229:
 
{{WH}}
 
{{WH}}
 
{{WS}}
 
{{WS}}
 +
[[Category: (name of the system)]]

Latest revision as of 22:03, 19 September 2018

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: M. Khurram Afzal, MD [2], Sogand Goudarzi, MD

Differentiating [disease name] from other diseases on the basis of [symptom 1], [symptom 2], and [symptom 3]

On the basis [symptom 1], [symptom 2], and [symptom 3], [disease name] must be differentiated from [disease 1], [disease 2], [disease 3], [disease 4], [disease 5], and [disease 6].

Diseases Clinical manifestations Para-clinical findings Gold standard Additional findings
Symptoms Physical examination
Lab Findings Imaging
Symptoms of DVT Symptoms of Pulmonary Embolism Symptoms of Myocardial Infarction Tenderness in extremities Edema in extremities Warmth in extremities PT aPTT Doppler ultrasound Chest CT scan
Antithrombin III deficiency[1][2][3] + + - + + + Normal
  • Normal
  • Reduces the Increase in PTT after administration of heparin
Factor V Leiden mutation[4][5][6][7][8] + + + + + + N/A
  • N/A
  • Inactivates factor Va and factor VIIIa
Protein C deficiency[9][10][11] + + - + + + Normal Normal / ↑
Protein S deficiency[11][12][13] + + - + + + Normal Normal / ↑
Prothrombin gene mutation[14][15][16] + + - + + + N/A
Disseminated intravascular coagulation (DIC)[17][18][19] + + +/- + + +
  • N/A
Antiphospholipid antibody syndrome[20][21][22][23][24] + + +/- + + + N/A

References

  1. Patnaik MM, Moll S (November 2008). "Inherited antithrombin deficiency: a review". Haemophilia. 14 (6): 1229–39. PMID 19141163. doi:10.1111/j.1365-2516.2008.01830.x. 
  2. Al Hadidi, Samer; Wu, Kristi; Aburahma, Ahmed; Alamarat, Zain (2017). "Family with clots: antithrombin deficiency". BMJ Case Reports: bcr–2017–221556. ISSN 1757-790X. doi:10.1136/bcr-2017-221556. 
  3. Konecny F (January 2009). "Inherited trombophilic states and pulmonary embolism". J Res Med Sci. 14 (1): 43–56. PMC 3129068Freely accessible. PMID 21772860. 
  4. Mannucci PM, Asselta R, Duga S, Guella I, Spreafico M, Lotta L, Merlini PA, Peyvandi F, Kathiresan S, Ardissino D (October 2010). "The association of factor V Leiden with myocardial infarction is replicated in 1880 patients with premature disease". J. Thromb. Haemost. 8 (10): 2116–21. PMID 20626623. doi:10.1111/j.1538-7836.2010.03982.x. 
  5. Campello E, Spiezia L, Simioni P (December 2016). "Diagnosis and management of factor V Leiden". Expert Rev Hematol. 9 (12): 1139–1149. PMID 27797270. doi:10.1080/17474086.2016.1249364. 
  6. Van Rooden CJ, Rosendaal FR, Meinders AE, Van Oostayen JA, Van Der Meer FJ, Huisman MV (February 2004). "The contribution of factor V Leiden and prothrombin G20210A mutation to the risk of central venous catheter-related thrombosis". Haematologica. 89 (2): 201–6. PMID 15003896. 
  7. Dentali F, Pomero F, Borretta V, Gianni M, Squizzato A, Fenoglio L; et al. (2013). "Location of venous thrombosis in patients with FVL or prothrombin G20210A mutations: systematic review and meta-analysis.". Thromb Haemost. 110 (1): 191–4. PMID 23615845. doi:10.1160/TH13-02-0163. 
  8. Press RD, Bauer KA, Kujovich JL, Heit JA (November 2002). "Clinical utility of factor V leiden (R506Q) testing for the diagnosis and management of thromboembolic disorders". Arch. Pathol. Lab. Med. 126 (11): 1304–18. PMID 12421138. doi:10.1043/0003-9985(2002)126<1304:CUOFVL>2.0.CO;2. 
  9. Bernard Khor & Elizabeth M. Van Cott (2010). "Laboratory tests for protein C deficiency". American journal of hematology. 85 (6): 440–442. PMID 20309856. doi:10.1002/ajh.21679. 
  10. Pescatore SL (March 2001). "Clinical management of protein C deficiency". Expert Opin Pharmacother. 2 (3): 431–9. PMID 11336597. doi:10.1517/14656566.2.3.431. 
  11. 11.0 11.1 Gustavo A. Rodriguez-Leal, Segundo Moran, Roberto Corona-Cedillo & Rocio Brom-Valladares (2014). "Portal vein thrombosis with protein C-S deficiency in a non-cirrhotic patient". World journal of hepatology. 6 (7): 532–537. PMID 25068006. doi:10.4254/wjh.v6.i7.532. 
  12. Kristi J. Smock, Elizabeth A. Plumhoff, Piet Meijer, Peihong Hsu, Nicole D. Zantek, Nahla M. Heikal & Elizabeth M. Van Cott (2016). "Protein S testing in patients with protein S deficiency, factor V Leiden, and rivaroxaban by North American Specialized Coagulation Laboratories". Thrombosis and haemostasis. 116 (1): 50–57. PMID 27075008. doi:10.1160/TH15-12-0918. 
  13. Ji M, Yoon SN, Lee W, Jang S, Park SH, Kim DY, Chun S, Min WK (October 2011). "Protein S deficiency with a PROS1 gene mutation in a patient presenting with mesenteric venous thrombosis following total colectomy". Blood Coagul. Fibrinolysis. 22 (7): 619–21. PMID 21799399. doi:10.1097/MBC.0b013e32834a0421. 
  14. Cooper PC, Rezende SM (2007). "An overview of methods for detection of factor V Leiden and the prothrombin G20210A mutations.". Int J Lab Hematol. 29 (3): 153–62. PMID 17474891. doi:10.1111/j.1751-553X.2007.00892.x. 
  15. McGlennen RC, Key NS (2002). "Clinical and laboratory management of the prothrombin G20210A mutation.". Arch Pathol Lab Med. 126 (11): 1319–25. PMID 12421139. doi:10.1043/0003-9985(2002)126<1319:CALMOT>2.0.CO;2. 
  16. Dentali F, Pomero F, Borretta V, Gianni M, Squizzato A, Fenoglio L; et al. (2013). "Location of venous thrombosis in patients with FVL or prothrombin G20210A mutations: systematic review and meta-analysis.". Thromb Haemost. 110 (1): 191–4. PMID 23615845. doi:10.1160/TH13-02-0163. 
  17. Venugopal A (September 2014). "Disseminated intravascular coagulation". Indian J Anaesth. 58 (5): 603–8. PMC 4260307Freely accessible. PMID 25535423. doi:10.4103/0019-5049.144666. 
  18. Makruasi N (November 2015). "Treatment of Disseminated Intravascular Coagulation". J Med Assoc Thai. 98 Suppl 10: S45–51. PMID 27276832. 
  19. Cui S, Fu Z, Feng Y, Xie X, Ma X, Liu T; et al. (2018). "The disseminated intravascular coagulation score is a novel predictor for portal vein thrombosis in cirrhotic patients with hepatitis B.". Thromb Res. 161: 7–11. PMID 29178991. doi:10.1016/j.thromres.2017.11.010. 
  20. Lim W (2013). "Antiphospholipid syndrome". Hematology Am Soc Hematol Educ Program. 2013: 675–80. PMID 24319251. doi:10.1182/asheducation-2013.1.675. 
  21. Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M, De Groot PG (October 2009). "Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis". J. Thromb. Haemost. 7 (10): 1737–40. PMID 19624461. doi:10.1111/j.1538-7836.2009.03555.x. 
  22. Lim W (2013). "Antiphospholipid syndrome.". Hematology Am Soc Hematol Educ Program. 2013: 675–80. PMID 24319251. doi:10.1182/asheducation-2013.1.675. 
  23. Garcia D, Erkan D (2018). "Diagnosis and Management of the Antiphospholipid Syndrome.". N Engl J Med. 378 (21): 2010–2021. PMID 29791828. doi:10.1056/NEJMra1705454. 
  24. Kornacki J, Wirstlein P, Skrzypczak J (2012). "[Assessment of uterine arteries Doppler in the first half of pregnancy in women with thrombophilia].". Ginekol Pol. 83 (12): 916–21. PMID 23488294. 

Linked-in.jpg